Menu Search
Equities

CanBas Co Ltd

4575:TYO

CanBas Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,274.00
  • Today's Change-5.00 / -0.39%
  • Shares traded3.96m
  • 1 Year change+38.48%
  • Beta-0.7756
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year CanBas Co Ltd had revenues remain flat at 0.00, though the company grew net income from a loss of 1.24bn to a smaller loss of 1.21bn.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-53.54%
Return on equity-56.62%
Return on investment-56.62%
More ▼

Cash flow in JPYView more

In 2024, CanBas Co Ltd increased its cash reserves by 16.71%, or 270.41m. Cash Flow from Financing totalled 1.54bn or -- of revenues. In addition the company used 1.28bn for operations while cash used for investing totalled .
Cash flow per share-31.09
Price/Cash flow per share--
Book value per share129.88
Tangible book value per share129.88
More ▼

Balance sheet in JPYView more

CanBas Co Ltd has little financial risk as the capital structure does not rely on leverage.
Current ratio25.10
Quick ratio25.09
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.